EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Fibroblast heterogeneity in Peutz–Jeghers syndrome: identifying the polyp‐driving subset †

Takashi Nishina iD

The Journal of Pathology · 2026-12 · 270 (4) · 411-415

DOI: 10.1002/path.70112 ↗

At a glance

Übersichtsarbeit in The Journal of Pathology, published online on 2026-08-19. Written by Takashi Nishina. Institution: Department of Biochemistry, Faculty of Medicine, Toho University, Ota-ku, Tokyo, Japan. Major MEDLINE topics: Peutz-Jeghers Syndrome, Fibroblasts. 15 references. Funded by: Japan Society for the Promotion of Science, Cancer Research Institute, Kanazawa University, Cell Science Research Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Peutz–Jeghers syndrome (PJS) is a rare autosomal dominant disorder caused by germline mutations in STK11 , and is characterized by gastrointestinal hamartomatous polyps, the recurrent development of which significantly impacts patients' quality of life. While stromal cells have been implicated in PJS polyp formation, their specific characteristics remain unclear. Domènech‐Moreno et al identify polyp‐enriched crypt top fibroblasts (pCTFs) as the pathogenic fibroblast population and demonstrate that interleukin (IL)‐11, a major secretory factor produced by these cells, serves as a critical mediator linking STK11 deficiency to epithelial proliferation. The study reveals that Stk11 loss triggers IL‐11 expression, which in turn reinforces the pathogenic pCTF phenotype through autocrine signaling, forming a feedforward loop. Importantly, IL‐11 neutralization significantly reduces polyp formation in a faithful mouse model, providing strong preclinical evidence for therapeutic translation. This work represents a significant advance in our understanding of PJS pathogenesis and establishes IL‐11 as a promising therapeutic target. Future investigations into the effects of IL‐11 neutralization on established polyps will further refine the translational potential of these findings for preventive intervention strategies. © 2026 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Peutz-Jeghers SyndromeFibroblastsHumansAnimalsProtein Serine-Threonine KinasesInterleukin-11AMP-Activated Protein Kinase KinasesSignal Transduction

Author keywords

Interleukin‐11Peutz–Jeghers syndromeSTK11/LKB1fibroblast heterogeneityhamartomatous polypsstromal‐epithelial interaction

Substances

Protein Serine-Threonine KinasesInterleukin-11AMP-Activated Protein Kinase KinasesSTK11 protein, human

Authors and institutions

  • Department of Biochemistry, Faculty of Medicine, Toho University, Ota-ku, Tokyo, Japan.

ORCID profiles: Takashi Nishina

Funding

  • Japan Society for the Promotion of Science
  • Cancer Research Institute, Kanazawa University
  • Cell Science Research Foundation
  • Takeda Science Foundation
  • Daiichi Sankyo Foundation of Life Science
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research

Cite

APA

Nishina, T. (2026). Fibroblast heterogeneity in Peutz–Jeghers syndrome: identifying the polyp‐driving subset †. The Journal of Pathology, 270(4), 411-415. https://doi.org/10.1002/path.70112

Vancouver

Nishina T. Fibroblast heterogeneity in Peutz–Jeghers syndrome: identifying the polyp‐driving subset †. The Journal of Pathology. 2026;270(4):411-415. doi:10.1002/path.70112

BibTeX
@article{Nishina2026,
  author = {Nishina, Takashi},
  title = {Fibroblast heterogeneity in Peutz–Jeghers syndrome: identifying the polyp‐driving subset †},
  journal = {The Journal of Pathology},
  year = {2026},
  volume = {270},
  number = {4},
  pages = {411--415},
  doi = {10.1002/path.70112}
}
Start for free →